Resmetirom May Guard Against Fatty Liver-Linked Liver Cancer, Study Finds
A HKU-led preclinical study using a fatty liver disease mouse model and single-cell RNA sequencing suggests Resmetirom, FDA-approved for MAFLD, could prevent or slow fatty liver–related liver cancer by lowering the cancer-promoting MDK pathway and reshaping immune cells. Resmetirom reduced liver fat and tumor growth and lowered MDK levels, with stronger effects when combined with MDK inhibitors. Researchers plan biomarker validation and clinical trials combining Resmetirom with immunotherapy or targeted therapies to pursue a prevention-first approach for high-risk patients.
